The National Association of Community Health Centers (NACHC) strongly urged the U.S. Health and Human Services Secretary Xavier Becerra yesterday “to swiftly impose” fines on drug manufacturers that restrict shipments of 340B-purchased drugs to contract pharmacies and “hold manufacturers accountable for the breach” of their 340B pharmaceutical pricing agreements.
“Pharmaceutical manufacturers have callously and unlawfully chosen to restrict health centers’ access to 340B priced medications,” NACHC Interim President and CEO Rachel Gonzales-Hanson said in a June 16 letter to Becerra. “Health centers continue to experience devastating financial losses as we wait for final decisions in the alternative dispute resolution (ADR) process and ongoing federal court litigation.”
The National Association of Community Health Centers (NACHC) strongly urged the U.S. Health and Human Services Secretary Xavier Becerra yesterday “to swiftly impose” fines on drug manufacturers that restrict shipments of 340B-purchased drugs to contract pharmacies and “hold manufacturers accountable for the breach” of their 340B pharmaceutical pricing agreements.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
